2181 — Mabpharm Income Statement
0.000.00%
Last trade - 00:00- HK$1.88bn
- HK$2.09bn
- CNY258.23m
Annual income statement for Mabpharm, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 82.9 | 55.9 | 87.2 | 258 |
| Cost of Revenue | |||||
| Gross Profit | — | 66.1 | 40.5 | 75.2 | 219 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 181 | 372 | 260 | 287 | 376 |
| Operating Profit | -181 | -289 | -204 | -200 | -117 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -185 | -292 | -211 | -209 | -128 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -185 | -292 | -211 | -209 | -128 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -185 | -292 | -211 | -209 | -128 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -185 | -292 | -211 | -209 | -128 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.045 | -0.071 | -0.051 | -0.051 | -0.031 |